Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04539275 · ClinicalTrials.gov registry record · Phase 3
VA CoronavirUs Research and Efficacy Studies-1
A Phase 3 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
NCT04539275: Clinical Trial Phase 3 study, sponsored by VA Office of Research and Development.
NCT04539275 is a Phase 3 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04539275, a Phase 3 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with convalescent plasma improves the clinical outcomes of Veterans who are hospitalized and require supplemental oxygen due to COVID-19.
Interventions
- DRUG Convalescent Plasma
- OTHER Masked Saline Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04539275
The ClinicalTrials.gov registry entry for NCT04539275 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Convalescent Plasma is the first listed.
NCT04539275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04539275 about?
NCT04539275 is a clinical study titled "VA CoronavirUs Research and Efficacy Studies-1". The purpose of this study is to determine if treatment with convalescent plasma improves the clinical outcomes of Veterans who are hospitalized and require supplemental oxygen due to COVID-19.
What is the current status of trial NCT04539275?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2020-11-16. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT04539275?
The interventions under investigation include: Convalescent Plasma (DRUG), Masked Saline Placebo (OTHER).
Who is sponsoring clinical trial NCT04539275?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.